Premium
Parenteral versus oral iron therapy for adults and children with chronic kidney disease
Author(s) -
Webster Angela,
Hodson Elisabeth
Publication year - 2012
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2012.01660.x
Subject(s) - medicine , citation , kidney disease , pediatrics , library science , computer science
Ferritin (Figure 1: mean difference 243 mg/L) and transferrin saturation levels (mean difference 10%) were significantly increased by intravenous (IV) iron compared with oral iron, while haemoglobin levels were slightly increased (mean difference 0.9 g/dl). The required dose of erythropoiesis stimulating agents (ESA) was significantly reduced in dialysis patients receiving IV iron compared with oral iron (Figure 2). Any change in ESA dose could not be assessed in nondialysis patients due to lack of trial data. All-cause mortality, cardiovascular mortality, quality of life and patients’ adherence to oral iron did not differ significantly but were reported in few studies. Gastrointestinal adverse effects were significantly more common with oral iron while hypotensive and allergic reactions were significantly more common with IV iron. What are the findings based on?